)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
BrainsWay
BrainsWay (BWAY) investor relations material
BrainsWay Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary10 Nov, 2026
Executive summary
Q3 systems shipped rose 44% YoY to 130, bringing the installed base to ~2,080; revenue grew 34% to $18.146m and RPO rose 31% to ~$85m.
Growth reflected Deep TMS adoption, recurring-revenue momentum and operating leverage; operating cash flow was $6.183m.
Financial highlights
Q3 revenue was $18.146m versus $13.512m; 9M revenue was $50.784m versus $37.680m.
Q3 gross profit was $14.135m versus $10.159m; gross margin was 78% versus 75% in Q3 2025 and Q2 2026.
Q3 operating income was $2.590m versus $1.253m; net income was $2.222m versus $1.566m.
Adjusted EBITDA was $3.873m versus $2.021m; margin expanded to 21% from 15%.
9M operating income was $6.986m versus $2.407m; net income was $7.222m versus $4.700m.
Outlook and guidance
FY26 revenue, operating-income margin and Adjusted EBITDA are expected at the upper end of prior guidance, with potential to modestly exceed it.
Management expects gross-margin improvement through year-end and operating income at the upper end of guidance.
2027 OpEx is expected to rise 15%-20%; further margin gains depend on book-to-bill remaining around 1.3x-1.4x.
Recurring revenue and RPO support visibility into growth and profitability into 2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from BrainsWay
- Revenue growth and rising profitability support an expanding Deep TMS platform.BWAY
Investor presentation - Deep TMS adoption accelerates globally, driving strong recurring revenue and rapid financial growth.BWAYInvestor presentation
- Q2 2026 revenue up 35% YoY, margins and guidance raised, with strong cash flow and system growth.BWAYQ2 2026
- Rapid ARR growth, clinical leadership, and global expansion drive strong financial momentum.BWAYInvestor presentation
- Record revenue growth and profitability fueled by recurring revenue and clinical innovation.BWAYInvestor presentation
- Q1 revenue up 35%, net income doubled, and record Deep TMS shipments drive strong outlook.BWAYQ1 2026
- Record revenue and net income growth in 2025, with robust 2026 outlook and regulatory catalysts.BWAYQ4 2025
- Record Q3 revenue, higher profits, raised guidance, and FDA clearance drive future growth.BWAYQ3 2025
- 2024 revenue rose 29% to $41M, with 2025 growth guided at 20–24% and gross margin steady at 75%.BWAYQ4 2024
Next BrainsWay earnings date
Q4 202610 Mar, 2027
BrainsWay
Next BrainsWay earnings date
Q4 202610 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Brainsway Ltd., a commercial stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. The company offers Deep TMS device that uses magnetic current pulses to stimulate the brain safely and painlessly; and Deep TMS Coil that is attached to the dTMS device. It markets the BrainsWay Deep TMS system under the hElios brand name for treating various psychiatric and neurological disorders. Brainsway Ltd. has a license agreement with InSightec, Ltd., which is a co-owner of the exclusive license issued by the Technion-Israel Institute of Technology. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.